{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:27:13Z","timestamp":1776212833552,"version":"3.50.1"},"reference-count":44,"publisher":"American Society of Hematology","issue":"22","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The importance of genetic diagnosis for patients with hemophilia has been recently demonstrated. However, the pathological variant cannot be identified in some patients. Here, we aimed to identify the pathogenic intronic variant causing hemophilia A using induced pluripotent stem cells (iPSCs) from patients and genome editing. We analyzed siblings with moderate hemophilia A and without abnormalities in the F8 exon. Next-generation sequencing of the entire F8 revealed 23 common intron variants. Variant effect predictor software indicated that the deep intronic variant at c.5220-8563A&amp;gt;G (intron 14) might act as a splicing acceptor. We developed iPSCs from patients and used genome editing to insert the elongation factor 1\u03b1 promoter to express F8 messenger RNA (mRNA). Then, we confirmed the existence of abnormal F8 mRNA derived from aberrant splicing, resulting in a premature terminal codon as well as a significant reduction in F8 mRNA in iPSCs due to nonsense-mediated RNA decay. Gene repair by genome editing recovered whole F8 mRNA expression. Introduction of the intron variant into human B-domain\u2013deleted F8 complementary DNA suppressed factor VIII (FVIII) activity and produced abnormal FVIII lacking the light chain in HEK293 cells. Furthermore, genome editing of the intron variant restored FVIII production. In summary, we have directly proven that the deep intronic variant in F8 results in aberrant splicing, leading to abnormal mRNA and nonsense-mediated RNA decay. Additionally, genome editing targeting the variant restored F8 mRNA and FVIII production. Our approach could be useful not only for identifying causal variants but also for verifying the therapeutic effect of personalized genome editing.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010838","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T17:40:27Z","timestamp":1696441227000},"page":"7017-7027","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4054-6748","authenticated-orcid":false,"given":"Takafumi","family":"Hiramoto","sequence":"first","affiliation":[{"name":"1Department of Biochemistry, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4373-5050","authenticated-orcid":false,"given":"Hiroshi","family":"Inaba","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3004-8457","authenticated-orcid":false,"given":"Nemekhbayar","family":"Baatartsogt","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-3937","authenticated-orcid":false,"given":"Yuji","family":"Kashiwakura","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morisada","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan"},{"name":"3Center for Gene Therapy Research, Jichi Medical University, Shimotsuke, Tochigi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Kamoshita","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan"},{"name":"3Center for Gene Therapy Research, Jichi Medical University, Shimotsuke, Tochigi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nishimasu","sequence":"additional","affiliation":[{"name":"4Structural Biology Division, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-7008","authenticated-orcid":false,"given":"Osamu","family":"Nureki","sequence":"additional","affiliation":[{"name":"5Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5415-0854","authenticated-orcid":false,"given":"Ei","family":"Kinai","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5082-6394","authenticated-orcid":false,"given":"Tsukasa","family":"Ohmori","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan"},{"name":"3Center for Gene Therapy Research, Jichi Medical University, Shimotsuke, Tochigi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"issue":"14","key":"2023112812510694400_bib1","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s40265-022-01788-y","article-title":"Valoctocogene roxaparvovec: first approval","volume":"82","author":"Blair","year":"2022","journal-title":"Drugs"},{"issue":"4","key":"2023112812510694400_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-023-01845-0","article-title":"Etranacogene dezaparvovec: first approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"2023112812510694400_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12185-018-2513-4","article-title":"Advances in gene therapy for hemophilia: basis, current status, and future perspectives","volume":"111","author":"Ohmori","year":"2020","journal-title":"Int J Hematol"},{"issue":"7794","key":"2023112812510694400_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature"},{"issue":"6213","key":"2023112812510694400_bib5","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"issue":"7","key":"2023112812510694400_bib6","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2023112812510694400_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s43856-023-00286-w","article-title":"PAM-flexible Cas9-mediated base editing of a hemophilia B mutation in induced pluripotent stem cells","volume":"3","author":"Hiramoto","year":"2023","journal-title":"Commun Med"},{"issue":"12","key":"2023112812510694400_bib8","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/ajh.23557","article-title":"The Canadian \u201cNational Program for hemophilia mutation testing\u201d database: a ten-year review","volume":"88","author":"Rydz","year":"2013","journal-title":"Am J Hematol"},{"issue":"2","key":"2023112812510694400_bib9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/rth2.12031","article-title":"Identification of deep intronic individual variants in patients with hemophilia A by next-generation sequencing of the whole factor VIII gene","volume":"1","author":"Inaba","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2023112812510694400_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/ejh.13242","article-title":"Deep intronic variant c.5999-277G&gt;A of F8 gene may be a hot spot mutation for mild hemophilia A patients without mutation in exonic DNA","volume":"103","author":"Chang","year":"2019","journal-title":"Eur J Haematol"},{"issue":"5","key":"2023112812510694400_bib11","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/jth.14771","article-title":"The highly prevalent deletions in F8 intron 13 found in French mild hemophilia A patients result from both founder effect and recurrent de novo events","volume":"18","author":"Jourdy","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9","key":"2023112812510694400_bib12","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/jth.12339","article-title":"Deep intronic \u201cmutations\u201d cause hemophilia A: application of next generation sequencing in patients without detectable mutation in F8 cDNA","volume":"11","author":"Pezeshkpoor","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"2023112812510694400_bib13","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/j.1538-7836.2011.04408.x","article-title":"Deep intronic variations may cause mild hemophilia A","volume":"9","author":"Castaman","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"2023112812510694400_bib14","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/hae.14179","article-title":"The challenge of genetically unresolved haemophilia A patients: interest of the combination of whole F8 gene sequencing and functional assays","volume":"26","author":"Lassalle","year":"2020","journal-title":"Haemophilia"},{"issue":"5","key":"2023112812510694400_bib15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/hae.14134","article-title":"Identification of new F8 deep intronic variations in patients with haemophilia A","volume":"26","author":"Dericquebourg","year":"2020","journal-title":"Haemophilia"},{"issue":"4","key":"2023112812510694400_bib16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1046\/j.1365-2141.1999.01767.x","article-title":"Creation of a novel donor splice site in intron 1 of the factor VIII gene leads to activation of a 191\u00a0bp cryptic exon in two haemophilia A patients: cryptic exon activation in two haemophilia A patients","volume":"107","author":"Bagnall","year":"1999","journal-title":"Br J Haematol"},{"issue":"3","key":"2023112812510694400_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.gt.3302174","article-title":"Expression of human coagulation factor VIII in adipocytes transduced with the simian immunodeficiency virus agmTYO1-based vector for hemophilia A gene therapy","volume":"11","author":"Ogata","year":"2004","journal-title":"Gene Ther"},{"issue":"6408","key":"2023112812510694400_bib18","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1126\/science.aas9129","article-title":"Engineered CRISPR-Cas9 nuclease with expanded targeting space","volume":"361","author":"Nishimasu","year":"2018","journal-title":"Science"},{"issue":"8","key":"2023112812510694400_bib19","doi-asserted-by":"crossref","first-page":"e3505","DOI":"10.1002\/jgm.3505","article-title":"Successful liver transduction by re-administration of different adeno-associated virus vector serotypes in mice","volume":"25","author":"Baatartsogt","year":"2023","journal-title":"J\u00a0Gene Med"},{"issue":"8","key":"2023112812510694400_bib20","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.4049\/jimmunol.1900315","article-title":"Induction of I\u03baB\u03b6 augments cytokine and chemokine production by IL-33 in mast cells","volume":"204","author":"Ohto-Ozaki","year":"2020","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"2023112812510694400_bib21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/cmb.1997.4.311","article-title":"Improved splice site detection in Genie","volume":"4","author":"Reese","year":"1997","journal-title":"J\u00a0Comput Biol"},{"issue":"11","key":"2023112812510694400_bib22","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/j.1538-7836.2009.03615.x","article-title":"Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors","volume":"7","author":"Coppola","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2023112812510694400_bib23","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/hae.14602","article-title":"Clinical conditions and risk factors for inhibitor-development in patients with haemophilia: a decade-long prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2)","volume":"28","author":"Nogami","year":"2022","journal-title":"Haemophilia"},{"issue":"suppl 6","key":"2023112812510694400_bib24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/hae.13506","article-title":"Genotypes, phenotypes and whole genome sequence: approaches from the My Life Our Future haemophilia project","volume":"24","author":"Konkle","year":"2018","journal-title":"Haemophilia"},{"issue":"2","key":"2023112812510694400_bib25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/hae.14232","article-title":"Women and girls with haemophilia and bleeding tendencies: outcomes related to menstruation, pregnancy, surgery and other bleeding episodes from a retrospective chart review","volume":"27","author":"Chaudhury","year":"2021","journal-title":"Haemophilia"},{"issue":"suppl 6","key":"2023112812510694400_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"2023112812510694400_bib27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jpeds.2022.01.033","article-title":"Genome analysis in sick neonates and infants: high-yield phenotypes and contribution of small copy number variations","volume":"244","author":"Suzuki","year":"2022","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"2023112812510694400_bib28","doi-asserted-by":"crossref","first-page":"14824","DOI":"10.1038\/s41598-021-94307-0","article-title":"Characterization and visualization of murine coagulation factor VIII-producing cells in\u00a0vivo","volume":"11","author":"Hayakawa","year":"2021","journal-title":"Sci Rep"},{"issue":"24","key":"2023112812510694400_bib29","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1182\/blood-2014-02-554501","article-title":"Murine coagulation factor VIII is synthesized in endothelial cells","volume":"123","author":"Everett","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2023112812510694400_bib30","doi-asserted-by":"crossref","first-page":"a032862","DOI":"10.1101\/cshperspect.a032862","article-title":"Nonsense-mediated mRNA decay begins where translation ends","volume":"11","author":"Karousis","year":"2019","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"11","key":"2023112812510694400_bib31","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41588-019-0517-5","article-title":"The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy","volume":"51","author":"Lindeboom","year":"2019","journal-title":"Nat Genet"},{"issue":"10","key":"2023112812510694400_bib32","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/jmg.2004.029538","article-title":"Splicing in action: assessing disease causing sequence changes","volume":"42","author":"Baralle","year":"2005","journal-title":"J\u00a0Med Genet"},{"issue":"5992","key":"2023112812510694400_bib33","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/312326a0","article-title":"Characterization of the human factor VIII gene","volume":"312","author":"Gitschier","year":"1984","journal-title":"Nature"},{"issue":"9","key":"2023112812510694400_bib34","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00439-017-1809-4","article-title":"Deep intronic mutations and human disease","volume":"136","author":"Vaz-Drago","year":"2017","journal-title":"Hum Genet"},{"key":"2023112812510694400_bib35","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.omtn.2023.04.012","article-title":"Strategies for precise gene edits in mammalian cells","volume":"32","author":"Fichter","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"2023112812510694400_bib36","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3389\/fgene.2018.00691","article-title":"Methodologies for improving HDR efficiency","volume":"9","author":"Liu","year":"2018","journal-title":"Front Genet"},{"issue":"6","key":"2023112812510694400_bib37","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1172\/JCI120429","article-title":"Gene therapy and genome surgery in the retina","volume":"128","author":"DiCarlo","year":"2018","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"2023112812510694400_bib38","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/sctm.19-0261","article-title":"Endothelial cells derived from patients\u2019 induced pluripotent stem cells for sustained factor VIII delivery and the treatment of hemophilia A","volume":"9","author":"Rose","year":"2020","journal-title":"Stem Cells Transl Med"},{"issue":"6","key":"2023112812510694400_bib39","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.stemcr.2018.10.012","article-title":"Patient-specific iPSC-derived endothelial cells provide long-term phenotypic correction of hemophilia A","volume":"11","author":"Olgasi","year":"2018","journal-title":"Stem Cell Reports"},{"issue":"2","key":"2023112812510694400_bib40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3390\/cells12020301","article-title":"Advances in recellularization of decellularized liver grafts with different liver (stem) cells: towards clinical applications","volume":"12","author":"Toprakhisar","year":"2023","journal-title":"Cells"},{"issue":"11","key":"2023112812510694400_bib41","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/tri.14128","article-title":"Organoid transplant approaches for the liver","volume":"34","author":"Reza","year":"2021","journal-title":"Transpl Int"},{"issue":"7","key":"2023112812510694400_bib42","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.ymthe.2023.03.024","article-title":"CRISPR-Cas-mediated transcriptional modulation: the therapeutic promises of CRISPRa and CRISPRi","volume":"31","author":"Bendixen","year":"2023","journal-title":"Mol Ther"},{"issue":"7536","key":"2023112812510694400_bib43","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nature14136","article-title":"Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex","volume":"517","author":"Konermann","year":"2015","journal-title":"Nature"},{"key":"2023112812510694400_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2023.08.031","article-title":"An AsCas12f-based compact genome editing tool derived by deep mutational scanning and structural analysis","author":"Hino","year":"2023;186:1-16","journal-title":"Cell"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/22\/7017\/2110993\/blooda_adv-2023-010838-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/22\/7017\/2110993\/blooda_adv-2023-010838-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T12:51:58Z","timestamp":1701175918000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/22\/7017\/498207\/Genome-editing-of-patient-derived-iPSCs-identifies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":44,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023,11,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010838","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,17]]}}}